Literature DB >> 14647413

Phosphorylation of BRCA2 by the Polo-like kinase Plk1 is regulated by DNA damage and mitotic progression.

MiYoung Lee1, Matthew J Daniels, Ashok R Venkitaraman.   

Abstract

The breast cancer susceptibility protein, BRCA2, preserves chromosomal stability through roles in the repair of DNA double-strand breaks, and possibly, cell division. Post-translational modifications that may coordinate these functions remain poorly characterized. Here, we report that BRCA2 is a substrate for the mitotic Polo-like kinase, Plk1. BRCA2 undergoes phosphorylation in cells synchronously passing through the G2/M phases of cell cycle, when Plk1 expression and activity are maximal. Depletion of Plk1 by RNA interference suppresses BRCA2 modification. BRCA2 and Plk1 interact with one another in cell lysates, through a conserved region in BRCA2, which spans the eight BRC repeat motifs essential for its function in DNA repair. Within this region, residues positioned between BRC repeats--but not the repeat motifs themselves--are phosphorylated by Plk1. Interestingly, Plk1-mediated modification of BRCA2 during the G2/M phases is inhibited by treatment with the radiomimetic agent, adriamycin. Thus, our findings define a regulatory circuit for BRCA2 phosphorylation by Plk1 that is responsive to DNA damage as well as mitotic progression.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14647413     DOI: 10.1038/sj.onc.1207223

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  36 in total

1.  Inhibition of Polo-like kinase 1 prevents the growth of metastatic breast cancer cells in the brain.

Authors:  Yongzhen Qian; Emily Hua; Kheem Bisht; Stephan Woditschka; Konstantine W Skordos; David J Liewehr; Seth M Steinberg; Edi Brogi; Muzaffar M Akram; J Keith Killian; Daniel C Edelman; Marbin Pineda; Stephanie Scurci; Yan Y Degenhardt; Sylvie Laquerre; Thomas A Lampkin; Paul S Meltzer; Kevin Camphausen; Patricia S Steeg; Diane Palmieri
Journal:  Clin Exp Metastasis       Date:  2011-09-21       Impact factor: 5.150

Review 2.  Multifaceted polo-like kinases: drug targets and antitargets for cancer therapy.

Authors:  Klaus Strebhardt
Journal:  Nat Rev Drug Discov       Date:  2010-08       Impact factor: 84.694

3.  BRCA2 minor transcript lacking exons 4-7 supports viability in mice and may account for survival of humans with a pathogenic biallelic mutation.

Authors:  Eswary Thirthagiri; Kimberly D Klarmann; Anil K Shukla; Eileen Southon; Kajal Biswas; Betty K Martin; Susan Lynn North; Valentin Magidson; Sandra Burkett; Diana C Haines; Kathleen Noer; Roberta Matthai; Lino Tessarollo; Jadranka Loncarek; Jonathan R Keller; Shyam K Sharan
Journal:  Hum Mol Genet       Date:  2016-02-26       Impact factor: 6.150

4.  A function for cyclin D1 in DNA repair uncovered by protein interactome analyses in human cancers.

Authors:  Siwanon Jirawatnotai; Yiduo Hu; Wojciech Michowski; Joshua E Elias; Lisa Becks; Frederic Bienvenu; Agnieszka Zagozdzon; Tapasree Goswami; Yaoyu E Wang; Alan B Clark; Thomas A Kunkel; Tanja van Harn; Bing Xia; Mick Correll; John Quackenbush; David M Livingston; Steven P Gygi; Piotr Sicinski
Journal:  Nature       Date:  2011-06-08       Impact factor: 49.962

5.  A comprehensive functional characterization of BRCA2 variants associated with Fanconi anemia using mouse ES cell-based assay.

Authors:  Kajal Biswas; Ranabir Das; Blanche P Alter; Sergey G Kuznetsov; Stacey Stauffer; Susan L North; Sandra Burkett; Lawrence C Brody; Stefan Meyer; R Andrew Byrd; Shyam K Sharan
Journal:  Blood       Date:  2011-06-30       Impact factor: 22.113

6.  Polo-like kinase isoforms in breast cancer: expression patterns and prognostic implications.

Authors:  Wilko Weichert; Glen Kristiansen; Klaus-Jürgen Winzer; Mathias Schmidt; Volker Gekeler; Aurelia Noske; Berit-Maria Müller; Silvia Niesporek; Manfred Dietel; Carsten Denkert
Journal:  Virchows Arch       Date:  2005-03-23       Impact factor: 4.064

7.  Fanconi anemia proteins are required to prevent accumulation of replication-associated DNA double-strand breaks.

Authors:  Alexandra Sobeck; Stacie Stone; Vincenzo Costanzo; Bendert de Graaf; Tanja Reuter; Johan de Winter; Michael Wallisch; Yassmine Akkari; Susan Olson; Weidong Wang; Hans Joenje; Jan L Christian; Patrick J Lupardus; Karlene A Cimprich; Jean Gautier; Maureen E Hoatlin
Journal:  Mol Cell Biol       Date:  2006-01       Impact factor: 4.272

8.  Cyclin D1 promotes BRCA2-Rad51 interaction by restricting cyclin A/B-dependent BRCA2 phosphorylation.

Authors:  C Chalermrujinanant; W Michowski; G Sittithumcharee; F Esashi; S Jirawatnotai
Journal:  Oncogene       Date:  2015-09-21       Impact factor: 9.867

Review 9.  The role of polo-like kinase 1 in carcinogenesis: cause or consequence?

Authors:  Brian D Cholewa; Xiaoqi Liu; Nihal Ahmad
Journal:  Cancer Res       Date:  2013-11-21       Impact factor: 12.701

10.  Ortholog of BRCA2-interacting protein BCCIP controls morphogenetic responses during DNA replication stress in Ustilago maydis.

Authors:  Ninghui Mao; Qingwen Zhou; Milorad Kojic; José Pérez-Martín; William K Holloman
Journal:  DNA Repair (Amst)       Date:  2007-07-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.